Ion channels as therapeutic targets: a drug discovery perspective.

Ion channels are membrane proteins expressed in almost all living cells. The sequencing of the human genome has identified more than 400 putative ion channels, but only a fraction of these have been cloned and functionally tested. The widespread tissue distribution of ion channels, coupled with the plethora of physiological consequences of their opening and closing, makes ion-channel-targeted drug discovery highly compelling. However, despite some important drugs in clinical use today, as a class, ion channels remain underexploited in drug discovery and many existing drugs are poorly selective with significant toxicities or suboptimal efficacy. This Perspective seeks to review the ion channel family, its structural and functional features, and the diseases that are known to be modulated by members of the family. In particular, we will explore the structure and properties of known ligands and consider the future prospects for drug discovery in this challenging but high potential area.

[1]  A. MacKenzie,et al.  Sodium Channel Inhibitors Reduce DMPK mRNA and Protein , 2015, Clinical and translational science.

[2]  E. Keystone,et al.  Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine , 2012, Annals of the rheumatic diseases.

[3]  B. Zhorov,et al.  Architecture and Pore Block of Eukaryotic Voltage-Gated Sodium Channels in View of NavAb Bacterial Sodium Channel Structure , 2012, Molecular Pharmacology.

[4]  A. Takahara,et al.  Discovery and evaluation of selective N-type calcium channel blockers: 6-unsubstituted-1,4-dihydropyridine-5-carboxylic acid derivatives. , 2012, Bioorganic & medicinal chemistry letters.

[5]  A. Szallasi,et al.  TRP channels as therapeutic targets in airway disorders: a patent review , 2012, Expert opinion on therapeutic patents.

[6]  Wei-Hsin Sun,et al.  Targeting ASIC3 for pain, anxiety, and insulin resistance. , 2012, Pharmacology & therapeutics.

[7]  M. Hattori,et al.  Molecular mechanism of ATP binding and ion channel activation in P2X receptors , 2012, Nature.

[8]  Ron O. Dror,et al.  Mechanism of Voltage Gating in Potassium Channels , 2012, Science.

[9]  G. Kaczorowski,et al.  Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics. , 2012, ACS medicinal chemistry letters.

[10]  C. Mebus,et al.  Efficacy and Safety of CE-224,535, an Antagonist of P2X7 Receptor, in Treatment of Patients with Rheumatoid Arthritis Inadequately Controlled by Methotrexate , 2012, The Journal of Rheumatology.

[11]  R. MacKinnon,et al.  Crystal Structure of the Human K2P TRAAK, a Lipid- and Mechano-Sensitive K+ Ion Channel , 2012, Science.

[12]  S. Long,et al.  Crystal Structure of the Human Two–Pore Domain Potassium Channel K2P1 , 2012, Science.

[13]  Steven V. Fox,et al.  Discovery of a Pharmacologically Active Antagonist of the Two‐Pore‐Domain Potassium Channel K2P9.1 (TASK‐3) , 2012, ChemMedChem.

[14]  M. Hayden,et al.  Treatment of Nav1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker , 2012, PAIN.

[15]  O. McManus,et al.  Identification of Novel and Selective KV2 Channel Inhibitors , 2011, Molecular Pharmacology.

[16]  C. Lindsley,et al.  Discovery, Characterization, and Structure–Activity Relationships of an Inhibitor of Inward Rectifier Potassium (Kir) Channels with Preference for Kir2.3, Kir3.X, and Kir7.1 , 2011, Front. Pharmacol..

[17]  O. McManus,et al.  Selective inhibition of the K(ir)2 family of inward rectifier potassium channels by a small molecule probe: the discovery, SAR, and pharmacological characterization of ML133. , 2011, ACS chemical biology.

[18]  M. Wallace,et al.  Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development , 2011, Expert opinion on investigational drugs.

[19]  A. Atala Re: Inhibition of the Cation Channel TRPV4 Improves Bladder Function in Mice and Rats With Cyclophosphamide-Induced Cystitis , 2011 .

[20]  R. M. Dipardo,et al.  Identification of non-amidine inhibitors of acid-sensing ion channel-3 (ASIC3). , 2011, Bioorganic & medicinal chemistry letters.

[21]  Daniel L. Minor,et al.  Voltage-gated sodium channel (NaV) protein dissection creates a set of functional pore-only proteins , 2011, Proceedings of the National Academy of Sciences.

[22]  W. Catterall,et al.  THE CRYSTAL STRUCTURE OF A VOLTAGE-GATED SODIUM CHANNEL , 2011, Nature.

[23]  A. Kalgutkar,et al.  Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535. , 2011, Bioorganic & medicinal chemistry letters.

[24]  Eric Gouaux,et al.  Principles of activation and permeation in an anion-selective Cys-loop receptor , 2011, Nature.

[25]  Joseph J. Babcock,et al.  Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules , 2011, Acta Pharmacologica Sinica.

[26]  T. McIntosh,et al.  Identification of a Binding Motif in the S5 Helix That Confers Cholesterol Sensitivity to the TRPV1 Ion Channel* , 2011, The Journal of Biological Chemistry.

[27]  J. Atack,et al.  GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolytics. , 2011, Current topics in medicinal chemistry.

[28]  M. Mayer Structure and mechanism of glutamate receptor ion channel assembly, activation and modulation , 2011, Current Opinion in Neurobiology.

[29]  O. McManus,et al.  A potent and selective indole N-type calcium channel (Ca(v)2.2) blocker for the treatment of pain. , 2011, Bioorganic & medicinal chemistry letters.

[30]  D. Trauner,et al.  Pharmacology of ionotropic glutamate receptors: A structural perspective. , 2010, Bioorganic & medicinal chemistry.

[31]  Roderick MacKinnon,et al.  Solution structure and phospholipid interactions of the isolated voltage-sensor domain from KvAP. , 2010, Journal of molecular biology.

[32]  H. Choo,et al.  5-HT3 antagonists under development , 2010, Expert opinion on investigational drugs.

[33]  Neil A Castle,et al.  Pharmacological modulation of voltage-gated potassium channels as a therapeutic strategy , 2010, Expert opinion on therapeutic patents.

[34]  T. Strassmaier,et al.  Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis , 2010, Proceedings of the National Academy of Sciences.

[35]  Raymond Miller,et al.  A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin , 2010, Clinical pharmacokinetics.

[36]  A. Dolphin,et al.  A new look at calcium channel α2δ subunits , 2010, Current Opinion in Neurobiology.

[37]  Marie-Pierre Dubé,et al.  A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura , 2010, Nature Medicine.

[38]  R. Dingledine,et al.  Glutamate Receptor Ion Channels: Structure, Regulation, and Function , 2010, Pharmacological Reviews.

[39]  A. Mathie,et al.  SYMPOSIUM REVIEW: Gating of two pore domain potassium channels , 2010, The Journal of physiology.

[40]  Nir Ben-Tal,et al.  Targeting the voltage sensor of Kv7.2 voltage-gated K+ channels with a new gating-modifier , 2010, Proceedings of the National Academy of Sciences.

[41]  A. Kaczor,et al.  Molecular structure of ionotropic glutamate receptors. , 2010, Current medicinal chemistry.

[42]  Brian J. Smith,et al.  Domain Reorientation and Rotation of an Intracellular Assembly Regulate Conduction in Kir Potassium Channels , 2010, Cell.

[43]  David J Craik,et al.  The engineering of an orally active conotoxin for the treatment of neuropathic pain. , 2010, Angewandte Chemie.

[44]  Jianpeng Ma,et al.  Structure of the full-length Shaker potassium channel Kv1.2 by normal-mode-based X-ray crystallographic refinement , 2010, Proceedings of the National Academy of Sciences.

[45]  S. Senger,et al.  Synthesis and structure-activity relationships of a series of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor. , 2010, Bioorganic & medicinal chemistry letters.

[46]  M. Kassiou,et al.  P2X purinergic receptor ligands: recently patented compounds , 2010, Expert opinion on therapeutic patents.

[47]  P. Verhoest,et al.  Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.

[48]  Jeffrey J Clare,et al.  Targeting ion channels for drug discovery. , 2010, Discovery medicine.

[49]  R. Lewis,et al.  Use of Venom Peptides to Probe Ion Channel Structure and Function* , 2010, The Journal of Biological Chemistry.

[50]  Kari Stefansson,et al.  Several common variants modulate heart rate, PR interval and QRS duration , 2010, Nature Genetics.

[51]  Mark N. Wass,et al.  Genetic variation in SCN10A influences cardiac conduction , 2010, Nature Genetics.

[52]  John Dunlop,et al.  Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease. , 2010, Current topics in medicinal chemistry.

[53]  E. Gouaux,et al.  X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor , 2009, Nature.

[54]  A. Ferrer-Montiel,et al.  TRPA1 modulators in preclinical development , 2009, Expert opinion on therapeutic patents.

[55]  J. Defalco,et al.  Identification and characterization of novel TRPV4 modulators. , 2009, Biochemical and biophysical research communications.

[56]  A. Wickenden,et al.  The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site , 2009, Neuroscience Letters.

[57]  M. D. de Groot,et al.  Subtype‐selective targeting of voltage‐gated sodium channels , 2009, British journal of pharmacology.

[58]  P. Welling,et al.  A comprehensive guide to the ROMK potassium channel: form and function in health and disease. , 2009, American journal of physiology. Renal physiology.

[59]  T. Nayak,et al.  Inhibition of Human Two-Pore Domain K+ Channel TREK1 by Local Anesthetic Lidocaine: Negative Cooperativity and Half-of-Sites Saturation Kinetics , 2009, Molecular Pharmacology.

[60]  Mark Furber,et al.  Antagonists of the P2X7 Receptor. From Lead Identification to Drug Development , 2009 .

[61]  D. Strøbæk,et al.  Selective Activation of the SK1 Subtype of Human Small-Conductance Ca2+-Activated K+ Channels by 4-(2-Methoxyphenylcarbamoyloxymethyl)-piperidine-1-carboxylic Acid tert-Butyl Ester (GW542573X) Is Dependent on Serine 293 in the S5 Segment , 2009, Molecular Pharmacology.

[62]  S. Ferro,et al.  Combined Strategies for the Discovery of Ionotropic Glutamate Receptor Antagonists , 2009, ChemMedChem.

[63]  A. Szallasi,et al.  TRP channels and pain. , 2009, Current pharmaceutical design.

[64]  J. Gever,et al.  Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. , 2009, Bioorganic & medicinal chemistry letters.

[65]  J. Gever,et al.  Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. , 2009, Bioorganic & medicinal chemistry letters.

[66]  N. Gavva Setbacks in the Clinical Development of TRPV1 Antagonists: What Next? , 2009 .

[67]  A. Takahara,et al.  Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. , 2009, Current topics in medicinal chemistry.

[68]  Thomas Friedrich,et al.  Refinement of the Binding Site and Mode of Action of the Anticonvulsant Retigabine on KCNQ K+ Channels , 2009, Molecular Pharmacology.

[69]  W. Luo,et al.  Clinical Pharmacokinetics of XP13512, a Novel Transported Prodrug of Gabapentin , 2008, Journal of clinical pharmacology.

[70]  R. Polosa,et al.  Potassium channels as drug targets for therapeutic intervention in respiratory diseases , 2008 .

[71]  S. England Voltage-gated sodium channels: the search for subtype-selective analgesics , 2008, Expert opinion on investigational drugs.

[72]  S. Dib-Hajj,et al.  Inherited Neuronal Ion Channelopathies: New Windows on Complex Neurological Diseases , 2008, The Journal of Neuroscience.

[73]  D. Strøbæk,et al.  Synthesis and Structure−Activity Relationship Studies of 2-(N-Substituted)-aminobenzimidazoles as Potent Negative Gating Modulators of Small Conductance Ca2+-Activated K+ Channels , 2008 .

[74]  A. Patapoutian,et al.  Identification of Transmembrane Domain 5 as a Critical Molecular Determinant of Menthol Sensitivity in Mammalian TRPA1 Channels , 2008, The Journal of Neuroscience.

[75]  J. Hieble,et al.  AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome. , 2008, American journal of physiology. Renal physiology.

[76]  D. Demarini,et al.  N-((1S)-1-{[4-((2S)-2-{[(2,4-Dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a Novel and Potent Transient Receptor Potential Vanilloid 4 Channel Agonist Induces Urinary Bladder Contraction and Hyperactivity: Part , 2008, Journal of Pharmacology and Experimental Therapeutics.

[77]  T. Cummins,et al.  Differential Block of Sensory Neuronal Voltage-Gated Sodium Channels by Lacosamide [(2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide], Lidocaine, and Carbamazepine , 2008, Journal of Pharmacology and Experimental Therapeutics.

[78]  L. Stanciu,et al.  Structure of TRPV1 channel revealed by electron cryomicroscopy , 2008, Proceedings of the National Academy of Sciences.

[79]  O. Cruz-López,et al.  The P2X7 receptor as a therapeutic target , 2008, Expert opinion on therapeutic targets.

[80]  K. Ataga,et al.  Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. , 2008, Blood.

[81]  R. Peri,et al.  High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology , 2008, Nature Reviews Drug Discovery.

[82]  D. Bowie Ionotropic glutamate receptors & CNS disorders. , 2008, CNS & neurological disorders drug targets.

[83]  W. Childers,et al.  Disruption of Kv1.1 N-type inactivation by novel small molecule inhibitors (disinactivators). , 2008, Bioorganic & medicinal chemistry.

[84]  J. La,et al.  Lamotrigine inhibits TRESK regulated by G-protein coupled receptor agonists. , 2008, Biochemical and biophysical research communications.

[85]  K. Watschinger,et al.  Pharmacological disruption of calcium channel trafficking by the α2δ ligand gabapentin , 2008, Proceedings of the National Academy of Sciences.

[86]  Su-Youne Chang,et al.  Acid-sensing ion channels (ASICs) as pharmacological targets for neurodegenerative diseases. , 2008, Current opinion in pharmacology.

[87]  A. Gomtsyan,et al.  Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management. , 2008, Journal of medicinal chemistry.

[88]  D. Henze,et al.  HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity , 2008, Molecular pain.

[89]  G. Lees,et al.  The Investigational Anticonvulsant Lacosamide Selectively Enhances Slow Inactivation of Voltage-Gated Sodium Channels , 2008, Molecular Pharmacology.

[90]  Clare London,et al.  Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. , 2007, Biochemistry.

[91]  E. Campbell,et al.  Atomic structure of a voltage-dependent K+ channel in a lipid membrane-like environment , 2007, Nature.

[92]  Sulayman D. Dib-Hajj,et al.  From genes to pain: Nav1.7 and human pain disorders , 2007, Trends in Neurosciences.

[93]  J. Treanor,et al.  Repeated Administration of Vanilloid Receptor TRPV1 Antagonists Attenuates Hyperthermia Elicited by TRPV1 Blockade , 2007, Journal of Pharmacology and Experimental Therapeutics.

[94]  David Julius,et al.  The menthol receptor TRPM8 is the principal detector of environmental cold , 2007, Nature.

[95]  D. Triggle Calcium channel antagonists: clinical uses--past, present and future. , 2007, Biochemical pharmacology.

[96]  E. Lingueglia Acid-sensing Ion Channels in Sensory Perception* , 2007, Journal of Biological Chemistry.

[97]  A. Patapoutian,et al.  TRPM8 Is Required for Cold Sensation in Mice , 2007, Neuron.

[98]  Christine Williams,et al.  Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade. , 2007, Journal of pharmacological and toxicological methods.

[99]  M. Dubé,et al.  Loss‐of‐function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations , 2007, Clinical genetics.

[100]  Joseph G McGivern,et al.  Advantages of voltage-gated ion channels as drug targets , 2007, Expert opinion on therapeutic targets.

[101]  David L Downie,et al.  Novel 384-Well Population Patch Clamp Electrophysiology Assays for Ca2+-Activated K+ Channels , 2007, Journal of biomolecular screening.

[102]  J. McGivern Ziconotide: a review of its pharmacology and use in the treatment of pain , 2007, Neuropsychiatric disease and treatment.

[103]  Peter G. Schultz,et al.  Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines , 2007, Nature.

[104]  C. Earnshaw,et al.  Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. , 2007, Bioorganic & medicinal chemistry letters.

[105]  D. Julius,et al.  TRP channel activation by reversible covalent modification , 2006, Proceedings of the National Academy of Sciences.

[106]  Hussain Jafri,et al.  An SCN9A channelopathy causes congenital inability to experience pain , 2006, Nature.

[107]  John A. Wemmie,et al.  Acid-sensing ion channels: advances, questions and therapeutic opportunities , 2006, Trends in Neurosciences.

[108]  Sui-Po Zhang,et al.  High-Throughput Screening for N-Type Calcium Channel Blockers Using a Scintillation Proximity Assay , 2006, Journal of biomolecular screening.

[109]  B. Khakh,et al.  P2X receptors as cell-surface ATP sensors in health and disease , 2006, Nature.

[110]  J. Feldon,et al.  Enhancing effects of nicotine and impairing effects of scopolamine on distinct aspects of performance in computerized attention and working memory tasks in marmoset monkeys , 2006, Neuropharmacology.

[111]  A. Randall,et al.  Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. , 2006, Bioorganic & medicinal chemistry letters.

[112]  E. Nisenbaum,et al.  LY404187: a novel positive allosteric modulator of AMPA receptors. , 2006, CNS drug reviews.

[113]  B. Jensen BMS-204352: a potassium channel opener developed for the treatment of stroke. , 2006, CNS drug reviews.

[114]  Michal Vieth,et al.  Dependence of molecular properties on proteomic family for marketed oral drugs. , 2006, Journal of medicinal chemistry.

[115]  P. Negulescu,et al.  Characterization of voltage-gated sodium-channel blockers by electrical stimulation and fluorescence detection of membrane potential , 2006, Nature Biotechnology.

[116]  Frances M. Ashcroft,et al.  From molecule to malady , 2006, Nature.

[117]  N Collinson,et al.  An Inverse Agonist Selective for α5 Subunit-Containing GABAA Receptors Enhances Cognition , 2006, Journal of Pharmacology and Experimental Therapeutics.

[118]  K. Gogas Glutamate-based therapeutic approaches: NR2B receptor antagonists. , 2006, Current opinion in pharmacology.

[119]  Oscar Casis,et al.  Mechanism of Action of a Novel Human ether-a-go-go-Related Gene Channel Activator , 2006, Molecular Pharmacology.

[120]  C. Gotti,et al.  Brain neuronal nicotinic receptors as new targets for drug discovery. , 2006, Current pharmaceutical design.

[121]  G. Dawson,et al.  TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an Agonist Selective for α2- and α3-Containing GABAA Receptors, Is a Nonsedating Anxiolytic in Rodents and Primates , 2006, Journal of Pharmacology and Experimental Therapeutics.

[122]  R. MacKinnon,et al.  Principles of Selective Ion Transport in Channels and Pumps , 2005, Science.

[123]  C. Kung,et al.  Prokaryotic K(+) channels: from crystal structures to diversity. , 2005, FEMS microbiology reviews.

[124]  G. Dubé,et al.  Electrophysiological and in vivo characterization of A-317567, a novel blocker of acid sensing ion channels , 2005, Pain.

[125]  E. Campbell,et al.  Crystal Structure of a Mammalian Voltage-Dependent Shaker Family K+ Channel , 2005, Science.

[126]  Bernd Nilius,et al.  TRP Channels in Disease , 2005, Science's STKE.

[127]  J. Atack The benzodiazepine binding site of GABAA receptors as a target for the development of novel anxiolytics , 2005, Expert opinion on investigational drugs.

[128]  Brian T. O’Neill,et al.  Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation , 2005 .

[129]  P. Taylor,et al.  Crystal structure of a Cbtx–AChBP complex reveals essential interactions between snake α‐neurotoxins and nicotinic receptors , 2005, The EMBO journal.

[130]  T. Neelands,et al.  BL-1249 [(5,6,7,8-Tetrahydro-naphthalen-1-yl)-[2-(1H-tetrazol-5-yl)-phenyl]-amine]: A Putative Potassium Channel Opener with Bladder-Relaxant Properties , 2005, Journal of Pharmacology and Experimental Therapeutics.

[131]  N. Unwin,et al.  Refined structure of the nicotinic acetylcholine receptor at 4A resolution. , 2005, Journal of molecular biology.

[132]  E. Wong,et al.  Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors. , 2005, Journal of medicinal chemistry.

[133]  P. Calabresi,et al.  Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. , 2004, Molecular pharmacology.

[134]  A. Chamberlin,et al.  Ligands for kainate subtype glutamate receptors , 2004 .

[135]  Desmond O'Connor,et al.  Selective, Orally Active γ-Aminobutyric AcidA α5 Receptor Inverse Agonists as Cognition Enhancers , 2004 .

[136]  S. Danthi,et al.  Caffeic acid esters activate TREK-1 potassium channels and inhibit depolarization-dependent secretion. , 2004, Molecular pharmacology.

[137]  G. Dawson,et al.  Identification of a Novel, Selective GABAA α5 Receptor Inverse Agonist Which Enhances Cognition , 2003 .

[138]  J. Scuvée-Moreau,et al.  Modulation of small conductance calcium-activated potassium (SK) channels: a new challenge in medicinal chemistry. , 2003, Current medicinal chemistry.

[139]  T. Brennan,et al.  A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[140]  T. Jentsch,et al.  Ion channel diseases. , 2002, Human molecular genetics.

[141]  G. Biggio,et al.  Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. , 2002, European journal of pharmacology.

[142]  K. Jacobson,et al.  Purine and pyrimidine (P2) receptors as drug targets. , 2002, Journal of medicinal chemistry.

[143]  N. Yoshida New Perspectives on the Structure and Function of the Na+ Channel Multigene Family , 2002 .

[144]  David Julius,et al.  Molecular Basis for Species-Specific Sensitivity to “Hot” Chili Peppers , 2002, Cell.

[145]  Rory Curtis,et al.  A Novel Membrane Potential-Sensitive Fluorescent Dye Improves Cell-Based Assays for Ion Channels , 2002, Journal of biomolecular screening.

[146]  Roderick MacKinnon,et al.  Energetic optimization of ion conduction rate by the K+ selectivity filter , 2001, Nature.

[147]  R. MacKinnon,et al.  Chemistry of ion coordination and hydration revealed by a K+ channel–Fab complex at 2.0 Å resolution , 2001, Nature.

[148]  D. Min,et al.  Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1 , 2001, Neuropharmacology.

[149]  G. Perrault,et al.  SL651498: An Anxioselective Compound with Functional Selectivity for α2- and α3-Containing γ-Aminobutyric AcidA (GABAA) Receptors , 2001 .

[150]  T. Sixma,et al.  Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors , 2001, Nature.

[151]  J. Wood,et al.  Voltage-gated sodium channels. , 2001, Current opinion in pharmacology.

[152]  P. Krogsgaard‐Larsen,et al.  Stereochemistry and molecular pharmacology of (S)-thio-ATPA, a new potent and selective GluR5 agonist. , 2001, European journal of pharmacology.

[153]  T. Jentsch Neuronal KCNQ potassium channels:physislogy and role in disease , 2000, Nature Reviews Neuroscience.

[154]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[155]  H. Arias,et al.  Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors , 2000, Neurochemistry International.

[156]  R. Mckernan,et al.  Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype , 2000, Nature Neuroscience.

[157]  B. Ballyk,et al.  4-Alkyl- and 4-cinnamylglutamic acid analogues are potent GluR5 kainate receptor agonists. , 2000, Journal of medicinal chemistry.

[158]  A. Patel,et al.  The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK. , 2000, Molecular pharmacology.

[159]  Stéphanie Baulac,et al.  Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2 , 2000, Nature Genetics.

[160]  Thomas Friedrich,et al.  KCNQ4, a Novel Potassium Channel Expressed in Sensory Outer Hair Cells, Is Mutated in Dominant Deafness , 1999, Cell.

[161]  G. Strichartz,et al.  Inhibition by local anesthetics of Ca2+ channels in rat anterior pituitary cells. , 1998, European journal of pharmacology.

[162]  I. Chessell,et al.  Blockade of human P2X7 receptor function with a monoclonal antibody , 1998 .

[163]  E. London,et al.  2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. , 1998, Journal of medicinal chemistry.

[164]  B. Chait,et al.  The structure of the potassium channel: molecular basis of K+ conduction and selectivity. , 1998, Science.

[165]  Xin-Yun Huang,et al.  Specific Antibodies to the External Vestibule of Voltage-gated Potassium Channels Block Current , 1998, The Journal of general physiology.

[166]  J J Baldwin,et al.  Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide. , 1997, Journal of medicinal chemistry.

[167]  W. J. Jackson,et al.  Functional Characterization of the Novel Neuronal Nicotinic Acetylcholine Receptor Ligand GTS-21 In Vitro and In Vivo , 1997, Pharmacology Biochemistry and Behavior.

[168]  R. Lifton,et al.  Genetic heterogeneity of Barter's syndrome revealed by mutations in the K+ channel, ROMK , 1996, Nature Genetics.

[169]  W. Catterall,et al.  Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[170]  W. Löscher,et al.  D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures , 1996, Epilepsy Research.

[171]  M. Collins,et al.  (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. , 1995, Journal of medicinal chemistry.

[172]  Arthur J Moss,et al.  SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome , 1995, Cell.

[173]  E. Green,et al.  A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.

[174]  E. Wong,et al.  The interaction of RS 25259‐197, a potent and selective antagonist, with 5‐HT3 receptors, in vitro , 1995, British journal of pharmacology.

[175]  Michael Litt,et al.  Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1 , 1994, Nature Genetics.

[176]  J. Watkins,et al.  Willardiines differentiate agonist binding sites for kainate- versus AMPA-preferring glutamate receptors in DRG and hippocampal neurons , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[177]  R. R. Frants,et al.  Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease , 1993, Nature Genetics.

[178]  R. Skelton,et al.  Differential effects of benzodiazepine receptor agonists on hippocampal long-term potentiation and spatial learning in the Morris water maze , 1993, Brain Research.

[179]  D. Faulds,et al.  Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. , 1992, Drugs.

[180]  A. Nishida,et al.  Pharmacologic profile of (R)-5-[(1-methyl-3-indolyl)carbonyl]-4,5,6,7-tetrahydro-1H- benzimidazole hydrochloride (YM060), a potent and selective 5-hydroxytryptamine3 receptor antagonist, and its enantiomer in the isolated tissue. , 1991, The Journal of pharmacology and experimental therapeutics.

[181]  F. Salituro,et al.  Activity of 5,7-dichlorokynurenic acid, a potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site. , 1990, Molecular pharmacology.

[182]  R. Miller,et al.  Ifenprodil is a novel type of N-methyl-D-aspartate receptor antagonist: interaction with polyamines. , 1989, Molecular pharmacology.

[183]  E. Costa,et al.  Kynurenate and 2-amino-5-phosphonovalerate interact with multiple binding sites of the N-methyl-d-aspartate-sensitive glutamate receptor domain , 1989, Neuroscience Letters.

[184]  B. Costall,et al.  The potential anxiolytic activity of GR38032F, a 5‐HT3‐receptor antagonist , 1988, British journal of pharmacology.

[185]  J. Wells,et al.  Sodium ions as blocking agents and charge carriers in the potassium channel of the squid giant axon , 1977, The Journal of general physiology.

[186]  T. M. Forrester,et al.  A comparison of the diuretic action of the chlorothiazide analogues. , 1959, Lancet.

[187]  B. Swahn,et al.  Recent Progress in the Discovery of Kv7 Modulators , 2011 .

[188]  D. Henze,et al.  Recent Advances Toward Pain Therapeutics , 2011 .

[189]  M. Kemp Structural trends among second-generation voltage-gated sodium channel blockers. , 2010, Progress in medicinal chemistry.

[190]  S. D. Kimball,et al.  Modulators of Transient Receptor Potential Ion Channels , 2010 .

[191]  R. M. Dipardo,et al.  Amidine derived inhibitors of acid-sensing ion channel-3 (ASIC3). , 2009, Bioorganic & medicinal chemistry letters.

[192]  T. Jegla,et al.  Evolution of the human ion channel set. , 2009, Combinatorial chemistry & high throughput screening.

[193]  V. Flockerzi An introduction on TRP channels. , 2007, Handbook of experimental pharmacology.

[194]  H. Arias,et al.  Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors. , 2006, The international journal of biochemistry & cell biology.

[195]  W. Sieghart Structure, pharmacology, and function of GABAA receptor subtypes. , 2006, Advances in pharmacology.

[196]  Miroslav Backonja,et al.  Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. , 2003, Clinical therapeutics.

[197]  M. Detheux,et al.  Aequorin-based functional assays for G-protein-coupled receptors, ion channels, and tyrosine kinase receptors. , 2002, Receptors & channels.

[198]  M. Mortimore,et al.  The medicinal chemistry of the P2 receptor family. , 2001, Progress in medicinal chemistry.

[199]  S. Hebert General principles of the structure of ion channels. , 1998, The American journal of medicine.

[200]  Kym M. Boycott,et al.  Loss-of-function mutations in a calcium-channel α1-subunit gene in Xp11.23 cause incomplete X-linked congenital stationary night blindness , 1998, Nature Genetics.

[201]  H. Fozzard,et al.  A structural model of the tetrodotoxin and saxitoxin binding site of the Na+ channel. , 1994, Biophysical journal.

[202]  I. Tarnawa,et al.  Structure-activity relationships of 2,3-benzodiazepine compounds with glutamate antagonistic action , 1993 .

[203]  M. Sakamori,et al.  Antagonistic activity of Y-25130 on 5-HT3 receptors. , 1992, Japanese journal of pharmacology.

[204]  H. Takeshima,et al.  Expression of functional sodium channels from cloned cDNA , 1986, Nature.

[205]  R. Sofia,et al.  [The pharmacologic effect of flupirtine, a structurally new analgesic]. , 1985, Arzneimittel-Forschung.

[206]  W. Schindler,et al.  Über Derivate des Iminodibenzyls , 1954 .